National Institute for Health and Care Excellence (NICE) - Articles and news items

ustekinumab

NICE recommends Janssen’s Crohn’s Disease biological therapy

Industry news / 2 May 2017 / Niamh Marriott, Junior Editor

NICE has recommended Stelara (ustekinumab) in its final appraisal determination as a treatment option for adult patients with Crohn’s disease…

multiple myeloma

NICE does not recommend Janssen’s multiple myeloma drug

Industry news / 29 March 2017 / Niamh Marriott, Junior Editor

NICE) has published new draft guidance not recommending daratumumab monotherapy (Darzalex, Janssen) to treat some people with multiple myeloma…

Price drops make more cancer drugs routinely available

Industry news / 7 March 2017 / Steve Bremer, Managing Editor

The National Institute for Health and Care Excellence (NICE) is half way through a review of drugs approved and still available only through the old Cancer Drugs Fund (CDF). In all cases so far where NICE has been able to make recommendations for routine NHS use, companies have reviewed and reduced their prices, and in some cases provided clearer evidence.

recommend

NICE does not recommend Merck’s lung cancer drug

Industry news / 2 March 2017 / Niamh Marriott, Digital Editor

NICE has published draft guidance which does not recommend Keytruda, also known as pembrolizumab, for untreated PD-L1-positive metastatic lung cancer…

UPDATE: The Cancer Drugs Fund

Blog, Industry news / 1 March 2017 / Niamh Louise Marriott, Digital Editor

This page will be updated as the results from the Cancer Drugs Fund appraisal are announced by The National Institute of Health and Care Excellence (NICE).

NICE does not recommend AbbVie’s leukaemia drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range…

Pfizer’s breast cancer drug too expensive for NHS

Industry news / 3 February 2017 / Niamh Marriott, Digital Editor

NICE has today published draft guidance which does not recommend Pfizer’s breast cancer drug palbociclib for routine funding on the NHS…

NICE approves former CDF kidney cancer drug for NHS use

Industry news / 12 January 2017 / Niamh Marriott, Digital Editor

Everolimus (Afinitor, Novartis) is now recommended to be available on the NHS as a treatment option for some patients with advanced renal cell carcinoma…

NICE says Roche’s trastuzumab emtansine too expensive for routine NHS use

Industry news / 29 December 2016 / Niamh Louise Marriott, Digital Editor

Trastuzumab emtansine is currently being funded through the Cancer Drugs Fund (CDF). NICE is looking again at its 2015 guidance to see whether it should…

NICE and FDA team up for technology collaboration

Industry news / 20 December 2016 / Niamh Louise Marriott, Digital Editor

The National Institute of Health and Care Excellence (NICE) and the United States’ Food and Drug Administration (FDA) will team up, using technology to…

pembrolizumab

Price drop and new data means NICE recommends lung cancer drug pembrolizumab

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

In earlier draft guidance, NICE’s appraisal committee had not recommended pembrolizumab as there were uncertainties about its long term benefits…

NICE recommends first-in-class severe asthma treatment

Industry news / 5 December 2016 / Niamh Louise Marriott, Digital Editor

Mepolizumab is the first biologic treatment to target specific white blood cells called eosinophils, which are responsible for symptoms of severe asthma…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+